Pharmacological management of antifungal agents in pulmonary aspergillosis: an updated review

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Echeverría Esnal, Daniel
• dc.contributor.author Martín-Ontiyuelo, Clara
• dc.contributor.author Navarrete Rouco, Maria Eugenia
• dc.contributor.author Barceló-Vidal, Jaime
• dc.contributor.author Conde Estévez, David
• dc.contributor.author Carballo Martínez, Núria
• dc.contributor.author De Antonio Cuscó, Marta
• dc.contributor.author Ferrández, Olivia
• dc.contributor.author Horcajada Gallego, Juan Pablo
• dc.contributor.author Grau Cerrato, Santiago
• dc.date.accessioned 2022-06-03T06:36:53Z
• dc.date.available 2022-06-03T06:36:53Z
• dc.date.issued 2022
• dc.description.abstract Introduction: Aspergillus may cause different types of lung infections: invasive, chronic pulmonary or allergic bronchopulmonary aspergillosis. Pharmacological management with antifungals poses as a challenge. Patients diagnosed with pulmonary aspergillosis are complex, as well as the problems associated with antifungal agents. Areas covered: This article reviews the pharmacology of antifungal agents in development and currently used to treat pulmonary aspergillosis, including the mechanisms of action, pharmacokinetics, pharmacodynamics, dosing, therapeutic drug monitoring and safety. Recommendations to manage situations that arise in daily clinical practice are provided. A literature search of PubMed was conducted on November 15th, 2020 and updated on March 30th, 2021. Expert opinion: Recent and relevant developments in the treatment of pulmonary aspergillosis have taken place. Novel antifungals with new mechanisms of action that extend antifungal spectrum and improve pharmacokinetic-related aspects, drug-drug interactions and safety are under current study. For those antifungals already marketed, new data related to pharmacokinetics, pharmacodynamics, dose adjustments in special situations, therapeutic drug monitoring and safety are available. To maximize efficacy and reduce the risk of associated toxicities, it is essential to choose the most appropriate antifungal; optimize its dose, interval, route of administration and length of treatment; and prevent side effects.
• dc.format.mimetype application/pdf
• dc.identifier.citation Echeverria-Esnal D, Martín-Ontiyuelo C, Navarrete-Rouco ME, Barcelo-Vidal J, Conde-Estévez D, Carballo N, et al. Pharmacological management of antifungal agents in pulmonary aspergillosis: an updated review. Expert Rev Anti Infect Ther. 2022 Feb; 20(2): 179-97. DOI: 10.1080/14787210.2021.1962292
• dc.identifier.doi http://dx.doi.org/10.1080/14787210.2021.1962292
• dc.identifier.issn 1478-7210
• dc.identifier.uri http://hdl.handle.net/10230/53383
• dc.language.iso eng
• dc.publisher Taylor & Francis
• dc.rights © This is an Accepted Manuscript of an article published by Taylor & Francis in Expert review of anti-infective therapy on 2022, available online: http://www.tandfonline.com/10.1080/14787210.2021.1962292 .
• dc.rights.accessRights info:eu-repo/semantics/embargoedAccess
• dc.subject.keyword Allergic bronchopulmonary aspergillosis
• dc.subject.keyword Aspergillus
• dc.subject.keyword Antifungals
• dc.subject.keyword Chronic pulmonary aspergillosis
• dc.subject.keyword Invasive aspergillosis
• dc.subject.keyword Isavuconazole
• dc.subject.keyword Liposomal amphotericin B
• dc.subject.keyword Pharmacology
• dc.subject.keyword Posaconazole
• dc.subject.keyword Voriconazole
• dc.title Pharmacological management of antifungal agents in pulmonary aspergillosis: an updated review
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/acceptedVersion